Using patient-derived organoids to predict lung cancer treatment response

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of patient-derived organoid (PDO) models in predicting the response of lung cancer patients to anti-cancer drugs. By establishing organoids from tumor biopsies, researchers will analyze the tumor characteristics and test the organoids' sensitivity to various chemotherapy regimens. The study will involve 50 cases over a period of three years, focusing on the consistency and accuracy of these models in guiding personalized treatment plans for lung cancer patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically proven lung cancer
* Age ≥ 18
* Written informed and signed consent
* Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour

Exclusion Criteria:

* Less than 18 years of age
* Not able to give informed consent (language, intellectual capacities, etc.)
* Not accessible to biopsy and/or surgery sample
* Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis.

Where it's running

• Geneva University Hospitals
  Geneva, Switzerland Recruiting

Study contacts

• Study coordinator: Veronique SERRE-BEINIER, PhD
• Email: veronique.serre-beinier@hcuge.ch
• Phone: (0)223795107

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden

  This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.

  Recruiting Tongji Hospital · Hubei, Wuhan · NCT07912190

• Organoid Drug Sensitivity-Guided Therapy for Refractory Tumors

  This study tests whether tumor organoids created from a patient’s tissue can help doctors pick drugs for adults with hard‑to-treat, unresectable, or metastatic cancers after standard options have been exhausted.

  Recruiting Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07906301

• Urine VOC Test to Detect Lung Cancer in Never Smokers

  A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07871656

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Duodenal organoids to study how the gut lining interacts with pathogens

  Researchers are using tissue from patients who have part of their duodenum removed to grow living 3D organoids and test how the intestinal epithelium responds to pathogens in the lab.

  Recruiting IRCCS Sacro Cuore Don Calabria di Negrar · Negrar, Verona · NCT07828665

• Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment

  This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07816263

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.